Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 31;13(10):2856-2860.
doi: 10.21037/tlcr-24-594. Epub 2024 Oct 17.

Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?

Alice Mogenet  1   2 , Laurent Greillier  1   2 , Pascale Tomasini  1   2
Affiliations
Editorial

Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?

Alice Mogenet et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Lung cancer; biomarkers; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-594/coif). A.M. received honoraria from Amgen, Oseus, Viatris, and AstraZeneca; received support for attending meetings from BMS and Takeda; and took part in the advisory board of Takeda, AstraZeneca and Pfizer. L.G. received honoraria from Amgen, BMS, Takeda, Sanofi, Pfizer, MSD, and AstraZeneca; and took part in the advisory board of Amgen, AstraZeneca, Takeda, Sanofi, Roche, Pfizer, Novartis, MSD and BMS. P.T. received honoraria from Lilly, Amgen, Janssen, and AstraZeneca; received support for attending meetings from BMS and Daiichi Sankyo; and took part in the advisory board of Amgen, Janssen, and AstraZeneca. The authors have no other conflicts of interest to declare.

Comment on

  • Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
    Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Parra ER, et al. Clin Cancer Res. 2024 Apr 15;30(8):1655-1668. doi: 10.1158/1078-0432.CCR-23-0251. Clin Cancer Res. 2024. PMID: 38277235 Free PMC article.

References

    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. Aguiar PN, Jr, De Mello RA, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 2017;9:499-506. 10.2217/imt-2016-0150 - DOI - PubMed
    1. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol 2015;10:985-9. 10.1097/JTO.0000000000000526 - DOI - PubMed

LinkOut - more resources